CheckMate 9ER Trial: ICI Provides Survival Benefit in Renal Cell Carcinoma
Dec 14, 2023
Relative to the previous standard of sunitinib, a combination of the checkpoint inhibitor nivolumab and the tyrosine kinase inhibitor cabozantinib improve overall survival (OS) in patients with advanced renal cell carcinoma (RCC), according to results from the phase 3 CheckMate 9ER trial.
Although not the only combination strategy to show an OS advantage over sunitinib (Sutent, Pfizer) for advanced RCC in a phase 3 trial, nivolumab (Opdivo, Bristol Myers Squibb) and cabozantinib (Cabometyx, Exelixis) represent “an important treatment option,” according to investigator Toni K. Choueiri, MD, the director of the Dana-Farber Cancer Institute’s Lank Center for Genitourinary Oncology, in Boston.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M.Read more…